These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 1971592

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551.
    McCaffrey PM, Riddell JG, Shanks RG.
    J Cardiovasc Pharmacol; 1988 May; 11(5):543-51. PubMed ID: 2455840
    [Abstract] [Full Text] [Related]

  • 3. Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods.
    Silke B, Hanratty CG, Riddell JG.
    J Cardiovasc Pharmacol; 1999 Jun; 33(6):859-67. PubMed ID: 10367588
    [Abstract] [Full Text] [Related]

  • 4. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
    McCaffrey PM, Riddell JG, Shanks RG.
    Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
    [Abstract] [Full Text] [Related]

  • 5. Comparative effects of beta-adrenoceptor partial agonists on isolated rat atrium.
    Vigholt-Sørensen E, Påby L, Halliday SE, Snow HM.
    Pharmacol Toxicol; 1991 Nov; 69(5):351-4. PubMed ID: 1687080
    [Abstract] [Full Text] [Related]

  • 6. Facilitation of norepinephrine release from cerebral cortex is mediated by beta 2-adrenergic receptors.
    Murugaiah KD, O'Donnell JM.
    Life Sci; 1995 Nov; 57(20):PL327-32. PubMed ID: 7475928
    [Abstract] [Full Text] [Related]

  • 7. The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog.
    Hadfield SE, Slee SJ, Snow HM.
    Br J Clin Pharmacol; 1989 Nov; 28 Suppl 1(Suppl 1):78S-81S. PubMed ID: 2572262
    [Abstract] [Full Text] [Related]

  • 8. Effect of beta-adrenoceptor agents on the blood flow in carotid arteries in normal volunteers.
    Fitzgerald DE, Harry JD.
    Br J Clin Pharmacol; 1989 Nov; 28 Suppl 1(Suppl 1):73S-74S. PubMed ID: 2572260
    [Abstract] [Full Text] [Related]

  • 9. beta(2) and beta(3)-adrenoceptor inhibition of alpha(1)-adrenoceptor-stimulated Ca(2+) elevation in human cultured prostatic stromal cells.
    Haynes JM.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):18-26. PubMed ID: 17617401
    [Abstract] [Full Text] [Related]

  • 10. The in vitro pharmacology of xamoterol (ICI 118,587).
    Malta E, Mian MA, Raper C.
    Br J Pharmacol; 1985 May 10; 85(1):179-87. PubMed ID: 2862938
    [Abstract] [Full Text] [Related]

  • 11. A comparison of the properties of prenalterol and corwin at beta 1- and beta 2-adrenoreceptors in vitro.
    Gurden JM, Apperley GH, Drew GM.
    J Auton Pharmacol; 1989 Apr 10; 9(2):79-91. PubMed ID: 2565903
    [Abstract] [Full Text] [Related]

  • 12. Effect of xamoterol on peripheral blood vessels in healthy subjects.
    Fitzgerald DE.
    Br J Clin Pharmacol; 1989 Apr 10; 28 Suppl 1(Suppl 1):70S-72S. PubMed ID: 2572259
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the effect on heart rate variability of a beta2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods.
    Hanratty CG, Silke B, Riddell JG.
    Br J Clin Pharmacol; 1999 Feb 10; 47(2):157-66. PubMed ID: 10190650
    [Abstract] [Full Text] [Related]

  • 14. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE, Cavero I, Manoury P, Lefevre-Borg F, Langer SZ.
    J Pharmacol Exp Ther; 1987 Sep 10; 242(3):1025-34. PubMed ID: 2888869
    [Abstract] [Full Text] [Related]

  • 15. Studies of the agonist and antagonist activity of cicloprolol in man.
    McCaffrey PM, Burke M, Riddell JG, Shanks RG.
    Eur J Clin Pharmacol; 1988 Sep 10; 34(6):569-75. PubMed ID: 3169110
    [Abstract] [Full Text] [Related]

  • 16. The electrophysiological effects of intravenous xamoterol in man.
    Bowes RJ, Gautam PC, Graham DR, Harley A.
    Eur J Clin Pharmacol; 1986 Sep 10; 29(6):731-4. PubMed ID: 2872057
    [Abstract] [Full Text] [Related]

  • 17. Effect of xamoterol on haemodynamics and plasma catecholamines in chronic heart failure.
    Ollivier JP, Ricordei I, Bayon P, Popelard P, Moyse D, de Bourayne J, Dupont C, Droniou J.
    Eur Heart J; 1990 Apr 10; 11 Suppl A():59-60. PubMed ID: 1971594
    [Abstract] [Full Text] [Related]

  • 18. Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone.
    Grove A, McFarlane LC, Lipworth BJ.
    Thorax; 1995 Feb 10; 50(2):134-8. PubMed ID: 7701450
    [Abstract] [Full Text] [Related]

  • 19. Evidence for an atypical, or beta 3-adrenoceptor in ferret tracheal epithelium.
    Webber SE, Stock MJ.
    Br J Pharmacol; 1992 Apr 10; 105(4):857-62. PubMed ID: 1354537
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
    Hattori Y, Sakuma I, Nakao Y, Kanno M.
    J Pharmacol Exp Ther; 1987 Sep 10; 242(3):1077-85. PubMed ID: 2888870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.